GleamWall
中文EN

CMPS COMPASS Pathways plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1816590 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY14.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-296.5%
ROA-68.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets72.6%
Debt / equity0.36x
Current ratio1.50x
Interest coverage-35.36x

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$23.46M$29.18M$26.48M$29.91M$27.32M$30.32M$30.88M$32.14M
SG&A expense$32.98M$23.20M$16.42M$16.05M$13.21M$12.61M$18.74M$16.27M
Operating income-$56.44M-$52.37M-$42.90M-$45.95M-$40.54M-$42.93M-$49.62M-$48.41M
Interest expense$1.50M$1.48M$1.47M$1.14M$1.10M$1.15M$1.12M$1.13M
Pretax income-$10.94M-$253.46M$91.19M-$96.61M-$137.95M-$38.27M-$17.51M-$42.31M
Income tax-$1.11M$331,000-$11,000-$2.73M-$230,000$137,000$354,000$1.02M
Net income-$9.83M-$253.79M$91.20M-$93.88M-$137.72M-$38.40M-$17.86M-$43.33M
EBITDA-$56.44M-$52.37M-$42.90M-$45.95M-$40.52M-$42.77M-$49.58M-$48.36M
EPS (basic)-0.07-1.880.71—-1.44-0.41-0.20—
EPS (diluted)-0.31-1.88-0.30—-1.44-0.41-0.24—
Weighted avg. shares (diluted)162.57M135.04M130.27M—95.34M93.34M98.64M—
Balance sheet
Cash & equivalents$443.98M$433.30M$466.01M$149.61M$185.94M$221.88M$260.11M$165.47M
Current assets$487.55M$475.67M$510.87M$191.49M$242.39M$276.40M$305.47M$201.29M
PP&E, net———————$189,000
Total assets$519.10M$504.56M$531.74M$210.35M$255.61M$293.54M$319.13M$213.67M
Current liabilities$325.86M$367.29M$153.80M$247.79M$197.45M$31.33M$30.00M$34.02M
Short-term debt$1.43M$0$0$17.52M$12.67M$7.98M$8.99M$5.51M
Long-term debt$49.56M$50.73M$50.48M$14.11M$18.60M$22.95M$21.55M$24.65M
Total debt$50.99M$50.73M$50.48M$31.63M$31.27M$30.93M$30.54M$30.16M
Total liabilities$377.03M$420.03M$205.05M$263.20M$218.02M$130.98M$123.67M$58.97M
Shareholders' equity$142.07M$84.53M$326.69M-$52.85M$37.59M$162.56M$195.47M$154.69M
Net debt-$392.99M-$382.57M-$415.53M-$117.97M-$154.67M-$190.95M-$229.57M-$135.31M
Shares outstanding141.68M135.72M134.92M96.09M96.00M93.59M92.85M68.55M
Cash flow statement
Operating cash flow-$50.77M-$40.31M-$47.94M-$37.79M-$35.11M-$38.69M-$45.66M-$41.76M
Capital expenditure———————$0
Free cash flow———————-$41.76M
Investing cash flow———————$0
Financing cash flow$63.09M$7.56M$362.45M$187,000$0$166,000$140.36M$155,000
Depreciation & amortization$0$0$0$6,000$15,000$158,000$37,000$50,000
Stock-based compensation$4.45M$4.03M$2.90M$2.85M$3.21M$3.60M$3.94M$4.49M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.